An observational study in Familial Hypercholesterolemia, sponsored by Children's Hospital of Fudan University. Recruiting at 6 sites in China. Open to participants aged 1 Year to 3 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Children's Hospital of Fudan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 13 under way, 7 of them phase 3. Hyperlipoproteinemia Type II · China.
Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is one of 3 that started in 2025, is one of 2 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 4th registered.
251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in China, United States, Australia and 17 more countries
Ages 6–17
Novartis Pharmaceuticals · Sites in China, United States, Austria and 8 more countries
Ages 2–11
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.
This study: 1 Year to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 14
First in 2018; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 770 across 64 observational studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 142 across the 22 interventional studies, 8,064 across the 2 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 24 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.
Children's Hospital of Fudan University has 1 study filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
3 of the studies in Hyperlipoproteinemia Type II with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05043181Tang-Du HospitalExosome-based Nanoplatform for Ldlr mRNA Delivery in FH | 2026-12 |
| NCT07695597CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia | 2027-04-30 |
| NCT07353398Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Child-parent screening for familial hypercholesterolemia has been proposed to identify children and their parent who are carrier of mutations and with high risk for inherited premature coronary artery disease. The investigators assessed the efficacy and feasibility of such screening in primary care practice.
key scientific questions:
Familial hypercholesterolemia (FH) is an inherited condition resulting in high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of premature coronary artery disease in men and women. Child-parent screening for familial hypercholesterolemia has been proposed to identify persons who are carriers of FH mutations and with high risk for inherited premature coronary artery disease. The investigators will conduct a cross-sectional community-based screening in children of 2 years old to detect FH children cases using finger blood TC test first and followed by serum TC test and mutation test, and to identify and diagnose their affected parents. This study aims to established the child-parent screening program and technique issues for early diagnosis of familial hypercholesterolemia families for future early intervention.
Child-parent screening strategy in our study consists three steps: i. Capillary blood total cholesterol test of children aged around 2 years; ii. re-test for children with cholesterol>95th percentile in the first step; iii. WES (whole exome sequencing) test for >P99 in the first two steps. iV: TC test and mutation test to the parents of the child FH cases. The investigators will determine FH families based on the program. Children's Hospital of Fudan University will provide treatment further.
All community-children from slelected communities aged 1 to 3 who receive regular child care (programmed immunization vaccination clinic) within a prespecified study period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
it is a observational study, do not have interventions.
The affected status of Familial Hypercholesterolemia
heterozygote or homozygote carriers of established FH mutations in LDLR, PSCK9 and APOB gene, including mutations included in the FH48 and new ones identified in Chinese children
Time frame: At enrollment
fasting total cholesterol level by Fingertip capillary blood test in children around 2 years old
Time frame: At enrollment
affected status of known FH mutation
according to FH48
Time frame: At enrollment
fasting serum LDL-c levels of children with finger TC over P95
Time frame: At enrollment
Plan to share: Undecided — The data generated and/or during current study are not publicly available due to incomplete study, but are available from the corresponding author on reasonable request.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Sep 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →
Children's Hospital of Fudan University →